Strategic Process. The agreement with Seattle Genetics follows a 13 months-long competitive strategic process led over the past several months by outside financial advisor, Xxxxxxxxx & Co. (“Greenhill”), which was retained for their global capabilities and their significant experience in biopharma M&A and licensing transactions. Xxxxxxxxx & Co. reports directly to the Transaction Committee of the Board, composed exclusively of the Company’s five independent directors. Xxxxx Xxxxx, independent Vice Chairman of the Immunomedics Board, stated, “We are pleased to offer Immunomedics stockholders the compelling and significant value provided by this agreement with Seattle Genetics. This agreement is the culmination of a robust strategic process, led by Greenhill and the Transaction Committee. Xxxxxxxxx’x outreach was to more than 45 parties and involved more than half of those parties entering into confidentiality agreements and participating in diligence. In addition to the highly competitive financial terms of the transaction, we believe that Seattle Genetics is the ideal partner for IMMU-132.”
Appears in 4 contracts
Samples: Development and License Agreement (Immunomedics Inc), Development and License Agreement (Seattle Genetics Inc /Wa), Development and License Agreement (Immunomedics Inc)